Loading
Cheap, essential chemotherapy drugs like cisplatin run out because making them is not profitable enough. A non-profit maker could guarantee supply at a fair price.
The 2023 US shortages of cisplatin and carboplatin, and recurrent shortages of methotrexate, vincristine and other generic oncology drugs, arise from thin margins, concentrated manufacturing and quality failures at single plants. Civica Rx, a non-profit founded by US health systems, has shown that a mission-driven manufacturer with long-term hospital contracts can stabilise supply of generic hospital injectables. The proposal is a non-profit oncology generics manufacturer or a Civica oncology division, with multi-year purchase commitments from health systems and dual-sourced active ingredients, initially for the ten most shortage-prone oncology injectables.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Prices and value, Most of the world has almost no cancer care, Platinum agents, Carboplatin.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.